Chemed Corp
Change company Symbol lookup
Select an option...
CHE Chemed Corp
ASTA WorldFlix Inc
$NQDM15LMCADN Nasdaq Developed Markets Telecommuni
BFZ BlackRock California Municipal Income Trust
CAR Avis Budget Group Inc
GIS General Mills Inc
VLN Valens Semiconductor Ltd
CIF MFS? Intermediate High Income Fund
LVOXW LiveVox Holdings Inc *W EXP 06/18/2026
SASR Sandy Spring Bancorp Inc
Go

Health Care : Health Care Providers & Services | Mid Cap Blend
Company profile

Chemed Corporation purchases, operates, and divests subsidiaries engaged in diverse business activities. The Company operates through two segments: the VITAS segment and Roto-Rooter segment. The VITAS segment provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers. The Company's VITAS business is operated in the state of Florida. Roto-Rooter segment provides plumbing, drain cleaning, excavation, water restoration and other related services to residential and commercial customers. Its services are provided through a network of company-owned branches, independent contractors, and franchisees. The Company's subsidiaries include Chemed RT, Inc., Comfort Care Holdings Co., Comfort Care Holdings Co. and others.

Closing Price
$430.12
Day's Change
12.45 (2.98%)
Bid
--
Ask
--
B/A Size
--
Day's High
431.43
Day's Low
417.61
Volume
(Light)
Volume:
94,641

10-day average volume:
118,739
94,641

Moderna to Build State-of-the-Art mRNA Facility in Africa to Manufacture up to 500 Million Doses Per Year

2:00 am ET October 7, 2021 (BusinessWire) Print

--Moderna will invest in building mRNA capabilities in Africa

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it will build a state-of-the-art mRNA facility in Africa with the goal of producing up to 500 million doses of vaccines each year at the 50 ug dose level. The Company anticipates investing up to $500 million in this new facility which is expected to include drug substance manufacturing with the opportunity for fill/finish and packaging capabilities at the site. The Company expects to begin a process for country and site selection soon.

"Since Moderna's founding in 2010, our mission has been to make a transformative impact on human lives through our medicines. After a decade of pioneering the development of our mRNA platform, we have been humbled to play a critical role in combatting the COVID-19 pandemic globally with our mRNA vaccine. We view Moderna's work as only just beginning," said Stephane Bancel, Moderna's Chief Executive Officer. "On behalf of our growing team, partners and shareholders, we are determined to extend Moderna's societal impact through the investment in a state-of-the-art mRNA manufacturing facility in Africa. While we are still working to increase capacity in our current network to deliver vaccines for the ongoing pandemic in 2022, we believe it is important to invest in the future. We expect to manufacture our COVID-19 vaccine as well as additional products within our mRNA vaccine portfolio at this facility."

Moderna and its partners have ramped up capacity worldwide and have supplied more than 500 million doses of Moderna's COVID-19 vaccine to date. As recently announced, there are several efforts to continue increasing capacity at a significant pace. This announcement is a new investment aimed at adding a manufacturing site in Africa to Moderna's expanding global network.

Moderna's pipeline includes 20 vaccine candidates in its prophylactic vaccines modality including vaccines against respiratory viruses, vaccines against latent viruses and vaccines against threats to global public health.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Company's plans to invest in a manufacturing facility in Africa for mRNA medicines; the scale of output for that manufacturing facility; and the total investment in the facility. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading "Risk Factors" in Moderna's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211006006058/en/

SOURCE: Moderna, Inc.

Media: 
Colleen Hussey
Director, Corporate Communications
617-335-1374
Colleen.Hussey@modernatx.com

Investors: 
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
comtex tracking

COMTEX_394712933/1006/2021-10-07T02:00:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.